API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-28-2024-59068.pdf
https://www.prnewswire.com/news-releases/mallinckrodt-presents-new-data-on-terlivaz-terlipressin-for-injection-at-the-society-of-critical-care-medicine-sccm-2024-critical-care-congress-302039708.html
https://www.prnewswire.com/news-releases/mallinckrodt-announces-journal-publication-of-economic-evidence-for-terlivaz-terlipressin-for-injection-in-adults-with-hepatorenal-syndrome-hrs-302020357.html
https://www.prnewswire.com/news-releases/mallinckrodt-to-present-breadth-of-data-on-terlivaz-terlipressin-for-injection-in-adult-patients-with-hepatorenal-syndrome-hrs-at-the-american-association-for-the-study-of-liver-diseases-aasld-2023-liver-meeting-301980866.html
https://www.prnewswire.com/news-releases/mallinckrodt-to-present-data-on-terlivaz-terlipressin-for-injection-in-adult-patients-with-hepatorenal-syndrome-hrs-at-the-american-society-of-nephrology-asn-kidney-week-2023-scientific-meeting-301973221.html
https://www.prnewswire.com/news-releases/mallinckrodt-to-present-data-on-terlivaz-terlipressin-for-injection-in-adult-patients-with-hepatorenal-syndrome-hrs-at-the-american-college-of-gastroenterology-acg-annual-scientific-meeting-301963752.html
https://www.prnewswire.com/news-releases/mallinckrodt-to-present-data-on-terlivaz-terlipressin-for-injection-in-adult-patients-with-hepatorenal-syndrome-hrs-at-the-european-association-for-the-study-of-the-liver-easl-congress-2023-301851370.html
https://www.prnewswire.com/news-releases/mallinckrodt-presents-clinical-data-for-terlivaz-terlipressin-for-injection-in-adults-with-hepatorenal-syndrome-hrs-at-the-american-transplant-congress-atc-2023-301839089.html
https://www.prnewswire.com/news-releases/mallinckrodt-presents-clinical-data-for-terlivaz-terlipressin-for-injection-in-adults-with-hepatorenal-syndrome-hrs-at-digestive-disease-week-ddw-2023-301811418.html
https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come
https://www.prnewswire.com/news-releases/mallinckrodt-to-present-data-on-terlivaz-terlipressin-for-injection-in-adult-patients-with-hepatorenal-syndrome-hrs-at-the-american-association-for-the-study-of-liver-diseases-aasld-2022-liver-meeting-301667057.html
https://www.prnewswire.com/news-releases/mallinckrodt-to-present-data-on-terlivaz-terlipressin-for-injection-in-adult-patients-with-hepatorenal-syndrome-hrs-at-the-american-college-of-gastroenterology-acg-annual-scientific-meeting-301656655.html
https://endpts.com/ema-makes-new-recommendations-for-imbruvica-medicines-with-terlipressin-over-respiratory-and-cardiovascular-risks/
https://www.fiercepharma.com/pharma/mallinckrodt-scores-long-awaited-fda-nod-treat-life-threatening-liver-condition
https://www.prnewswire.com/news-releases/mallinckrodt-receives-us-fda-approval-for-terlivaz-terlipressin-for-injection-for-the-treatment-of-hepatorenal-syndrome-hrs-301624894.html
https://www.prnewswire.com/news-releases/mallinckrodt-announces-data-at-kidney-week-2020-reimagined-that-showed-a-potential-for-reduced-need-for-renal-replacement-rrt-therapy-for-patients-with-hepatorenal-syndrome-type-1-hrs-1-treated-with-terlipressin-301162369.html
http://www.pharmatimes.com/news/us_committee_backs_terlipressin_approval_for_hrs-1_1344987
https://www.fiercebiotech.com/biotech/fda-panel-to-chew-over-endpoint-safety-strategies-for-mallinckrodt-s-terlipressin
https://www.prnewswire.com/news-releases/mallinckrodt-confirms-that-us-food-and-drug-administration-fda-will-convene-an-advisory-committee-to-review-terlipressin-for-the-treatment-of-patients-with-hepatorenal-syndrome-type-1-hrs-1-301089164.html
https://www.prnewswire.com/news-releases/real-world-data-of-terlipressin-in-hospitalized-patients-in-uk-with-hepatorenal-syndrome-type-1-hrs-1-published-in-alimentary-pharmacology-and-therapeutics-301074172.html
https://www.prnewswire.com/news-releases/mallinckrodt-announces-us-food-and-drug-administration-fda-filing-acceptance-of-new-drug-application-for-terlipressin-for-treatment-of-hepatorenal-syndrome-type-1-hrs-1-301044909.html
https://www.prnewswire.com/news-releases/mallinckrodt-completes-rolling-submission-of-new-drug-application-to-the-us-food-and-drug-administration-fda-for-terlipressin-for-the-treatment-of-patients-with-hepatorenal-syndrome-type-1-hrs-1-301025237.html
https://www.prnewswire.com/news-releases/mallinckrodt-presents-positive-phase-3-results-from-its-confirm-study-of-terlipressin-in-patients-with-hepatorenal-syndrome-type-1-hrs-1-at-the-liver-meeting-2019-300955532.html
https://www.prnewswire.com/news-releases/mallinckrodt-presents-positive-phase-3-results-from-its-confirm-study-of-terlipressin-in-patients-with-hepatorenal-syndrome-type-1-hrs-1-at-the-liver-meeting-2019-300955532.html
https://www.prnewswire.com/news-releases/mallinckrodt-to-present-results-from-its-pivotal-phase-3-confirm-study-of-terlipressin-in-patients-with-hepatorenal-syndrome-type-1-hrs-1-at-the-liver-meeting-2019-300942025.html
https://www.clinicaltrialsarena.com/news/mallinckrodt-terlipressin-confirm-data/
http://www.pharmatimes.com/news/government_to_reconsider_nhs_health_checks_1297765
https://endpts.com/ailing-mallinckrodts-drug-for-rare-life-threatening-renal-condition-clears-pivotal-study/
http://www.business-standard.com/article/companies/sun-ranbaxy-merger-cci-approves-divestment-of-seven-brands-to-emcure-115032300980_1.html